FDA Greenlights VUEWAY® for Use in Neonates and Infants, Improving MRI Safety The FDA has approved Bracco's VUEWAY® solution for pediatric MRIs, offering a safer low-dose contrast option for neonates, ensuring image quality while reducing gadolinium exposure.

FDA Greenlights VUEWAY® for Use in Neonates and Infants, Improving MRI Safety #Bracco #VUEWAY #gadopiclenol

European Commission Grants Pediatric Use Approval for Vueway® (gadopiclenol) by Bracco Imaging Bracco Imaging announces that the European Commission has extended Vueway®'s marketing authorization for pediatric patients under two, a significant advancement in diagnostic imaging.

European Commission Grants Pediatric Use Approval for Vueway® (gadopiclenol) by Bracco Imaging #Italy #Milan #Bracco_Imaging #VUEWAY #gadopiclenol

European Commission Approves Expanded Use of Vueway® for Pediatric Patients Bracco Imaging has announced that Vueway® (gadopiclenol) has received approval for use in pediatric patients under 2 in the EU, enhancing diagnostic options.

European Commission Approves Expanded Use of Vueway® for Pediatric Patients #None #Bracco_Imaging #VUEWAY #gadopiclenol

European Medicines Agency Approves Vueway® for Young Children Under 2 Bracco Imaging's Vueway® (gadopiclenol) has received a favorable opinion from the European Medicines Agency for use in pediatric patients under two years of age.

European Medicines Agency Approves Vueway® for Young Children Under 2 #Italy #Milan #Bracco_Imaging #VUEWAY #gadopiclenol

Bracco's Max 3 Syringeless MR Injector Receives FDA Expansion Approval Bracco Diagnostics has received FDA approval to expand the indications for its Max 3 Syringeless Injector, enhancing MRI contrast delivery efficiency.

Bracco's Max 3 Syringeless MR Injector Receives FDA Expansion Approval #USA #Princeton #Max_3 #Bracco_Imaging #VUEWAY

Bracco's Milestone Achievement: Over 3 Million Doses of VUEWAY® Administered to Patients Seeking Safer MRI Contrast Bracco Diagnostics has proudly announced the delivery of over 3 million doses of its innovative VUEWAY® MRI contrast agent, meeting the rising patient demand for lower-dosage options.

Bracco's Milestone Achievement: Over 3 Million Doses of VUEWAY® Administered to Patients Seeking Safer MRI Contrast #United_States #Princeton #Bracco_Diagnostics #VUEWAY #MRI_Contrast